74 results about "Intravenous therapy" patented technology

The present invention provides methods of treating or preventing atrial fibrillation, atrial flutter, or a combination thereof comprising intravenously administering sotalol hydrochloride to a subject in need thereof. Embodiments of the present invention further provide novel methods of intravenously administering sotalol hydrochloride for example in pediatric patients. The present invention provides a novel intravenous, prophylactic, antiarrhythmic method of sotalol administration.

The invention relates to medicine, in particular to gerontology and therapy and can be used for treating sarcopenia in elderly patients.Summary of the invention consists in alternating for 1…2 days the intravenous administration of ozonized 0.9% NaCl solution and major autohemotherapy, namely 500 mL of a 0.9% NaCl solution ozonized with an ozone-oxygen mixture, with an ozone concentration of 5…10 µg / mL, are administered, and major autohemotherapy consists in collecting 300…400 mL of venous blood from the patient, which is ozonized, with an ozone concentration of 15 µg / mL and transfused to the patient, the treatment course includes 8…10 consecutive procedures, then it is extended with minor autohemotherapy, which consists in collecting 5…10 mL of venous blood, which is ozonized, with an ozone concentration of 15 µg / mL and administered intramuscularly every 10th day of alternation and includes 3 consecutive procedures, and the ozonized 0.9% NaCl solution is administered for up to 6…8 weeks.

The application discloses a kind of hardness correlation liver cancer lung premetastatic niche mouse model construction method, it includes the following steps: (1) in vitro enrichment respectively on the low hardness substrate of hardness 6kPa and the high hardness substrate of hardness 16kPa, the condition culture supernatant of mouse liver cancer cell Hepa1-6 that is cultured and grows, respectively named mL-CM and mH-CM;(2) mL-CM and mH-CM are respectively injected into two groups of mice using tail vein injection mode, every 1 day injection 1 time, until the 26th day, during continuous monitoring the recruitment of BMDCs in fresh lung tissue, while with the induction endpoint, i.e. 26th day premetastatic niche mark feature detection includes lung tissue matrix remodeling, immunosuppression, angiogenesis, vascular permeability and inflammation etc..The method has the advantages of short modeling cycle, easy operation, controllable induction condition, can comprehensively and accurately evaluate the common characteristics of liver cancer lung premetastatic niche formation etc..

A venous monitoring system is disclosed that can include a fluid passageway formed in a housing to receive and direct fluid through the housing, a sensor coupled to the fluid passageway to detect data of the fluid in the fluid passageway, a communication unit to communicate data sensed by the sensor, and a power source, wherein the system of the present disclosure can be used for venous monitoring when coupled to a catheter or an intravenous set, or can include a catheter needle extending from the housing, and wherein the system of the present disclosure can detect characteristics such as placement of a catheter, fluid passageway occlusion or patency, and catheter extravasation or infiltration.

This invention discloses a phosphorylated diamine morpholino oligonucleotide drug that regulates PAPOLA expression and its application, belonging to the field of biomedical technology. The nucleotide sequence of the drug is shown in SEQ ID NO:1, targeting the coding region of human PAPOLA mRNA. The formulation is a lyophilized powder for injection, with excipients including mannitol and phosphate buffer. This invention also discloses the application of this drug in the preparation of a treatment for gastric cancer, specifically advanced gastric cancer with high PAPOLA expression. The drug is administered intravenously at a dose of 8-12 mg / kg every 3 days. Its mechanism of action is to block PAPOLA protein translation, inhibit the G1 / S phase transition of gastric cancer cells, and induce apoptosis. In vitro and in vivo experiments have confirmed that this drug can specifically inhibit the proliferation and growth of gastric cancer cells, providing a new treatment option for advanced gastric cancer.

Described herein are compositions, kits, and methods for potent delivery to a cell of a subject. The cell can be of a particular cell type, such as a basal cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled to a lipid composition. The lipid composition can comprise an ionizable cationic lipid, and a selective organ targeting lipid. The lipid composition can further comprise a phospholipid. Further described herein are high-potency intravenous dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.

The present disclosure provides a method of administering a low dose soluble protein to a subject in need thereof, wherein the method comprises (a) adding an intravenous solution stabilizer ("IVSS") to an isotonic aqueous solution in a container to form a pretreated container, (b) adding an amount from a protein stock solution to the pretreated container of step (a) to form a low dose protein solution, and (c) administering the low dose protein solution of step (b) to the subject. Optionally, the dose of the soluble protein to be administered to the subject is an ultra-low dose protein, wherein the low dose protein solution undergoes a further dilution step. In particular, the method of administering an ultra-low dose soluble protein comprises: (a) adding an IVSS to an isotonic aqueous solution in a first container to form a first pretreated container, (b) adding an amount from the protein stock solution to the first pretreated container to form a low dose protein solution; (c) adding an IVSS to an isotonic aqueous solution in a second container to form a second pretreated container; and (d) adding an amount of the low dose protein solution in step (b) to the second pretreated container of step (c) to form an ultra-low dose protein solution, and (e) administering the low dose protein solution of step (b) to an individual in need thereof.

This invention discloses a tactile-visual collaborative realistic simulation method for intravenous puncture in virtual training for intravenous therapy nurses, belonging to the field of medical virtual simulation training technology. Addressing the problems of single tactile feedback and poor coordination between tactile and visual feedback in existing systems, this invention uses layered collision modeling to detect the needle tip's level in real time and trigger events; it generates multi-level tactile and visual blood return feedback signals based on the needle tip level and outputs them synchronously based on the same event. This invention allows trainees to simultaneously experience the dual sensations of "feeling emptiness" and "stable blood return within the needle tube" during puncture, achieving close coordination between tactile and visual feedback and helping trainees establish correct neuromuscular memory. This invention can be widely applied in the field of virtual simulation training for nursing skills, significantly improving the realism of training and operational recognition.

[Problem] To provide a method for treatment of adenovirus infection or disease associated with adenovirus infection. [Solution] Provided is a pharmaceutical composition for use in the treatment of adenovirus infection or disease associated with adenovirus infection, comprising brincidofovir, a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein the treatment comprises (i) intravenously administering, to a human subject, the brincidofovir, pharmaceutically acceptable salt thereof, or solvate thereof at 0.38 to 0.42 mg / kg twice weekly, or (ii) intravenously administering, to a human subject, the brincidofovir, pharmaceutically acceptable salt thereof, or solvate thereof at 18 to 22 mg / dose twice weekly.

This invention discloses an antiepileptic magnetically responsive mechanoacturized targeted nanosystem, belonging to the field of biomedicine. The nanosystem, administered intravenously, accumulates in the epileptic focus area under the guidance of an external gradient magnetic field. Further, an alternating magnetic field triggers internal mechanoacturized units to generate mechanical movements such as rotation or vibration, thereby inducing structural changes in the drug-loading unit and achieving local release of the antiepileptic drug. The nanosystem can be further integrated with a blood-brain barrier-crossing targeting modification module and a monitoring module to improve lesion targeting and drug release controllability, and help reduce systemic exposure. This nanosystem can be used for the prevention and intervention of epilepsy.

This utility model relates to a simple experimental mouse fixation and tail vein injection device, including a fixation platform, a transparent isolation cover, and a tail fixation component. The transparent isolation cover is used to cover the experimental mouse on the fixation platform. An isolation cover notch is formed at the edge of the open end of the transparent isolation cover, through which the tail of the experimental mouse protrudes. The tail fixation component is used to fix the protruding tail of the experimental mouse on the fixation platform. This utility model combines experimental mouse fixation, tail fixation, and visual monitoring, achieving a dual improvement in drug administration accuracy and simplified experimental operation. It can be operated by a single person and is suitable for precise drug delivery and real-time image monitoring in small animal experiments, possessing high practical value and promising prospects for widespread application.

The present invention relates to a sustained-release biodegradable ophthalmic implant containing axitinib dispersed in a hydrogel for the long-term treatment of retinal diseases.

This invention provides a system for in-situ cardiac NO generation based on bioorthogonal reactions and its application, belonging to the pharmaceutical field. The system of this invention improves the bioavailability of NO in the heart, thereby significantly improving myocardial ischemia-reperfusion injury. Specifically, microneedles are pre-implanted into the heart, and then a delivery system (prepared by modifying L-arginine with trans-cyclooctene to form an L-arginine prodrug, and then preparing a nano-delivery system by electrostatic adsorption of L-Arg-TCO) is injected into the body via intravenous injection. Only when the nano-delivery system circulates to the heart, and the TCO undergoes a bioorthogonal reaction with (4-(6-methyl-1,2,4,5-tetraazinecyclo-3-yl)phenyl)methylamine in the microneedles, can the L-arginine prodrug be activated, thereby achieving cardiac-targeted delivery of L-arginine, leading to the enrichment, activation, and conversion of L-arginine into NO in the heart.

The application discloses application of a low-dose anti-PD-1 antibody in a limited course of treatment in treatment of hepatitis B. Anti-PD-1 antibody treatment is carried out on a chronic hepatitis B patient receiving nucleoside analogue or nucleotide analogue treatment, 100 mg is injected intravenously each time, once every three weeks, and the course of treatment is ended after 12 weeks or 24 weeks. The application blocks the combination of the PD-1 receptor highly expressed on the surface of T cells of the CHB patient with a ligand by blocking the CHB patient T cell surface high expression of the PD-1 receptor, thereby reversing the T cell exhaustion state, enhancing the HBV specific T cell immune response, and promoting HBsAg clearance. The application uses a limited course of treatment and a low-dose alpha PD-1 to enhance the HBV specific T cell immune response of the patient and promote the clearance of HBsAg while ensuring good safety. Compared with the traditional 48-week Peg-IFN alpha or several years or even decades of NAs treatment of the CHB patient, the 12-week or 24-week course of alpha PD-1 is shorter and has a smaller economic burden on the patient.

This invention belongs to the field of cell engineering technology, specifically relating to an engineered mitochondrial nanoshield, its preparation method, and its applications. The engineered mitochondrial nanoshield can resist damage from high concentrations of calcium ions in the extracellular environment, and also possesses BMMSCs targeting ability and ROS-responsive characteristics. After intravenous injection, the engineered mitochondrial nanoshield can selectively target BMMSCs to alleviate cellular senescence and increase bone mass in aged mice.

This invention discloses the application of a peptide SRD in the preparation of drugs for treating acute lung injury, belonging to the field of biomedical technology. In vivo experiments verified the protective effect of peptide SRD on acute lung injury (ALI), particularly its effect on improving AT2 mitochondrial function. In animal models of ALI, tail vein injection of peptide SRD significantly reduced the protein concentration and total cell count in bronchoalveolar lavage fluid, significantly alleviated the severity of lung injury, lowered histological scores, significantly decreased SOD2 acetylation levels while significantly increasing total SOD2 protein levels, and significantly increased SPC levels (an indicator of AT2 survival). ELISA analysis showed a significant decrease in the levels of IL-6, IL-1β, and TNF-α, indicators of pneumonia in mice. These experimental results confirm that the antioxidant peptide SRD can improve oxidative stress damage in ALI, effectively reduce AT2 cell damage under ALI conditions, promote AT2 regeneration and repair, effectively improve lung function, and reduce the inflammatory response of damaged lungs, thus exhibiting a good therapeutic effect on ALI.

Provided are a pharmaceutical composition of an analgesic compound and a preparation method therefor. The pharmaceutical composition can be prepared into a liquid injection or a lyophilized powder. The pharmaceutical composition has a controllable particle size and a narrow distribution range, features good stability, and can be used for intravenous injection and achieves a rapid onset of action, thereby effectively replacing the use of opioid analgesics and reducing addiction. In addition, the composition does not contain excipients having a sustained-release function, thereby providing higher safety.

This invention belongs to the field of biomedical inorganic nanomaterials technology, and discloses a copper-doped bioglass and its application in the treatment of chronic liver injury and hepatic osteodystrophy. The bioglass is prepared by a sol-gel method, with copper as a dopant (Cu). 2+ It is doped in a form with a doping amount of 0.1-5 wt%, has a mesoporous structure, a particle size of approximately 163 nm, and can slowly release Cu in environments with pH 7.4 or 5.5. 2+ The treatment duration is 48-96 hours. This invention is the first to use the aforementioned material for the simultaneous treatment of chronic liver injury (such as metabolic-associated steatohepatitis) and its secondary hepatic osteopathy, achieving liver-targeted therapy via intravenous injection. Its mechanism of action includes: regulating glucose and lipid metabolism in the liver, enhancing mitochondrial function, and inhibiting inflammation and fibrosis; simultaneously upregulating the liver-derived factor LCAT, promoting osteogenic differentiation via the liver-bone axis, thereby synergistically improving liver injury and bone loss. This invention overcomes the limitations of separate liver and bone treatment, providing a safe and effective integrated treatment strategy.

This application provides a hUC-MSC cell suspension formulation for treating allergic rhinitis and its preparation method. It comprises mammalian stem cells, a pharmaceutically acceptable suspension carrier, and a protective agent. The mammalian stem cells are mesenchymal stem cells, which can be derived from the human umbilical cord. The formulation is suitable for intravenous administration. The preparation method includes: washing the resuscitated stem cells with phosphate buffer, centrifuging, resuspending them in a suspension carrier, adding the suspension carrier and protective agent, and mixing thoroughly. Experiments show that this formulation can reduce the levels of interleukin-4 and interleukin-5 in the serum and spleen of mice with allergic rhinitis, and alleviate inflammatory cell infiltration in the nasal mucosa.

A stable intravenous (IV) composition comprises, in the intravenous form, nicotinamide riboside (NR) as described, or another nicotinyl riboside compound that is an NAD+ precursor. NR chloride may be provided in an intravenous (IV) formulation for administration to human subjects.

This invention discloses a yam vesicle nanomaterial, its preparation method, and its application for reducing the toxicity of radiotherapy for breast cancer. It belongs to the field of biomedical technology. The method includes adding PBS to the yam at a weight-to-volume ratio of 1:3 for juicing, sieving the yam juice, centrifuging the resulting yam filtrate at low speed to obtain supernatant A, centrifuging supernatant A at medium speed to obtain supernatant B, centrifuging supernatant B at ultra-high speed, resuspending the precipitate in PBS, and obtaining the yam vesicle nanomaterial. In this invention, the yam vesicle nanomaterial uses yam as raw material. The obtained yam vesicle nanomaterial has natural bone marrow targeting properties, requires no additional modification, and can spontaneously accumulate in the bone marrow after intravenous injection, specifically protecting the hematopoietic system. It can also simultaneously prevent the decrease in white blood cells, red blood cells, and platelets caused by radiotherapy, comprehensively alleviating the bone marrow suppression side effects of radiotherapy without affecting the efficacy of tumor radiotherapy.

The present application belongs to the technical field of nanometer material preparation, and relates to a kind of nanometer medicine, including medicine carrier and active ingredient, medicine carrier adopts amphiphilic polymer, and active ingredient includes photosensitizer Ce6 and analgesic drug LC. The preparation method of the nanometer medicine is also disclosed, comprising the following steps: weighing Ce6, analgesic drug LC and amphiphilic polymer, dissolving in solvent to obtain a mixed solution; the mixed solution is stirred uniformly, and dialyzed in ultrapure water; the solution obtained by dialysis is constant volume, and filtered to obtain nanometer medicine. The nanometer medicine particle size morphology is regular, the particle size is uniform, has good stability within 7 days, can have good enrichment effect at tumor site, and has good photodynamic therapy effect. Lidocaine and photosensitizer reach the lesion site at the same time through intravenous injection, not only reduce the operation steps, but also target the lesion site, reduce the anxiety of patients because they feel that anesthesia will affect intelligence.

This utility model discloses an auxiliary device for tail vein injection in medical experimental mice. Relating to the technical field of medical experimental equipment, the device includes a base with a fixing frame installed near the edge of the top. A fixing component is provided on the top of the base, and an observation component is provided on one outer wall of the fixing frame. The fixing component includes a lower fixing plate and an upper fixing plate, with the upper fixing plate positioned above the lower fixing plate. This auxiliary device for tail vein injection in medical experimental mice allows the upper fixing plate to move upward a certain distance by pulling a lever, overcoming the spring's thrust, and completely separating the upper and lower arc-shaped plates. The mouse is then placed on the lower arc-shaped plate. Releasing the lever causes the upper arc-shaped plate to move downward under the spring's thrust, thus securing the mouse and effectively avoiding the problem of mice being difficult to stabilize due to their active and restless nature.

This invention relates to the application of mitochondrial formulations in the preparation of drugs for treating chronic obstructive pulmonary disease (COPD). The mitochondrial formulations contain active mitochondria isolated from healthy donor cells, with a particle size of 400–1000 nm, possessing normal mitochondrial membrane potential and ATP generation function, and capable of being internalized by mammalian COPD lung epithelial cells. In vitro cell experiments have confirmed that this mitochondrial formulation can repair CSE-induced mitochondrial dysfunction in lung epithelial cells, inhibit mPTP opening, reduce mtDNA leakage into the cytoplasm, thereby blocking the activation of the cGAS-STING signaling pathway and reducing the release of inflammatory factors such as IL-1β and TNF-α. In vivo experiments in COPD mouse models show that tail vein injection of the mitochondrial formulation can effectively accumulate in lung tissue, significantly improving lung pathological changes such as emphysema and collagen fiber deposition in model mice. This invention provides a novel strategy for COPD treatment based on repairing mitochondrial function and intervening in inflammatory signaling pathways.

This invention discloses the application of induced pluripotent stem cell (EPC) derived from induced pluripotent stem cell differentiation in the preparation of stroke therapeutic agents. Through intravenous injection of EPCs into an animal model of stroke, this invention demonstrates that this method can treat stroke by inhibiting atherosclerosis, reducing cerebral infarction levels, promoting angiogenesis in lesioned brain tissue, improving inflammatory responses in lesioned brain tissue, and repairing nerve damage and brain injury. The above research results of this invention provide a new treatment method for stroke in clinical practice.

The invention discloses an application of a Lamp2b-IMTP fusion exosome in treatment of coronary heart disease. The specific application method comprises the following steps: preparing an exosome matrix, carrying out optimization treatment on the exosome matrix, and finally, specifically combining the optimized exosome matrix with myocardial cells through IMTP on the surface of the Lamp2b-IMTP fusion exosome in an intravenous injection administration mode. Therapeutic substances are accurately delivered to damaged myocardial tissues, which is the core advantage of the fused exosome and is also the basis of subsequent treatment effects: IMTP (myocardial targeting peptide) is modified on the surface of the exosome, and the IMTP can be accurately combined with a specific receptor on the surface of a damaged myocardial cell.

The present invention relates to a stable aqueous formulation of Leucovorin calcium designed for parenteral administration. This formulation utilizes substituted cyclodextrins, specifically Betadex sulfobutyl ether cyclodextrin (SBE-β-CD) or Hydroxypropyl Beta Cyclodextrin (HP-β-CD), as solubilizers and stabilizers to enhance the drug's aqueous solubility. The inclusion of Tromethamine serves as a buffering agent, maintaining optimal pH levels and ensuring the chemical stability of Leucovorin over an extended shelf life. Importantly, the formulation effectively prevents drug crystallization and particulate matter formation, addressing major stability challenges associated with existing products. The formulation's resilience to freeze-thaw cycles confirm its physical and chemical stability under stress conditions. These advancements not only improve the safety and efficacy of Leucovorin calcium for intravenous administration but also facilitate compliance with regulatory standards, providing a reliable therapeutic option for patients.

The present invention is directed to methods for treating or preventing neuroinflammation in a subject by administering an effective amount of a single-domain antibody (sdAb) comprising SEQ ID NO:1. The method is applicable to subjects with multiple sclerosis, including secondary progressive, primary progressive, and relapsing-remitting forms. Administration may be intravenous, subcutaneous, or intrathecal, with dosage regimens including daily administration, loading and maintenance doses, or continuous infusion. The method may be initiated upon first clinical signs of central nervous system demyelination and continued for at least 14 days. The sdAb may be co-administered with a pharmaceutically acceptable excipient such as mannitol, sucrose, or polysorbate 80, and optionally combined with disease-modifying therapies including interferon-β, glatiramer acetate, fingolimod, or ocrelizumab. The invention provides a targeted approach for modulating neuroinflammatory processes in neurological disorders.